Conditions: Breast Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 86
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether the combination of enzastaurin and capecitabine is more effective than the combination of placebo and capecitabine in treating participants with breast cancer who were previously treated with an anthracycline and a taxane.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: enzastaurin intervention 2: placebo intervention 3: capecitabine
Intervention descriptions: intervention 1: 1125 milligrams (mg) loading dose then 500 mg, oral, daily, 21-day cycles until progressive disease intervention 2: oral, daily, 21-day cycles until progressive disease intervention 3: 1250 mg/m\^2, BID, days 1-14 of each 21-day cycle until progressive disease

Protocol document: